Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 Ballot 3 World

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA

Page standards status: Informative

Raw xml | Download


<EvidenceVariable xmlns="http://hl7.org/fhir">
  <id value="236950"/>
  <meta>
    <versionId value="75"/>
    <lastUpdated value="2026-08-06T17:15:59.259Z"/>
    <profile
             value="http://hl7.org/fhir/uv/ebm/StructureDefinition/group-assignment"/>
  </meta>
  <language value="en"/>
  <text>
    <status value="extensions"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: EvidenceVariable 236950</b></p><a name="236950"> </a><a name="hc236950"> </a><div style="display: inline-block; background-color: #fbffeb; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">version: 75; Last updated: 2026-08-06 17:15:59+0000</p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-group-assignment.html">GroupAssignment</a></p></div><p><b>ArtifactPublicationStatus</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-status-type active}">Active</span></p><p><b>url</b>: <a href="EvidenceVariable-236950.html">EvidenceVariable GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA</a></p><p><b>identifier</b>: FEvIR Object Identifier/236950, FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-group-assignment-85394-85798, <a href="http://terminology.hl7.org/7.5.0/NamingSystem-uri.html" title="As defined by RFC 3986 (http://www.ietf.org/rfc/rfc3986.txt)(with many schemes defined in many RFCs). For OIDs and UUIDs, use the URN form (urn:oid:(note: lowercase) and urn:uuid:). See http://www.ietf.org/rfc/rfc3001.txt and http://www.ietf.org/rfc/rfc4122.txt 

This oid is used as an identifier II.root to indicate the the extension is an absolute URI (technically, an IRI). Typically, this is used for OIDs and GUIDs. Note that when this OID is used with OIDs and GUIDs, the II.extension should start with urn:oid or urn:uuid: 

Note that this OID is created to aid with interconversion between CDA and FHIR - FHIR uses urn:ietf:rfc:3986 as equivalent to this OID. URIs as identifiers appear more commonly in FHIR.

This OID may also be used in CD.codeSystem.">Uniform Resource Identifier (URI)</a>/urn:oid:2.16.840.1.113883.4.642.40.44.24.148</p><p><b>version</b>: 1.0.0-ballot3</p><p><b>name</b>: GroupAssignment_SGLT2_inhibitors_vs_GLP_1_RA</p><p><b>title</b>: GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA</p><p><b>citeAs</b>: </p><div><p>GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236950. Revised 2026-08-06. Available at: https://fevir.net/resources/EvidenceVariable/236950. Computable resource at: https://fevir.net/resources/EvidenceVariable/236950#json.</p>
</div><p><b>status</b>: Active</p><p><b>date</b>: 2026-11-05 14:34:28+0000</p><p><b>author</b>: Computable Publishing®: MAGIC-to-FEvIR Converter: </p><p><b>publisher</b>: HL7 International / Clinical Decision Support</p><p><b>contact</b>: HL7 International / Clinical Decision Support: <a href="http://www.hl7.org/Special/committees/dss">http://www.hl7.org/Special/committees/dss</a></p><p><b>description</b>: </p><div><p>This EvidenceVariable Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p>
</div><p><b>copyright</b>: </p><div><p>Copyright the Authors else Computable Publishing LLC. Noncommercial use permitted with CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). Commercial use permitted as agreed in Terms of Use (https://fevir.net/termsofuse).</p>
</div><h3>RelatesTos</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Target[x]</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/artifact-relationship-type part-of}">Part Of</span></td><td>MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)</td></tr></table><h3>Definitions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Concept</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 defined-in-handling-and-category}">Defined in handling and category elements</span></td></tr></table><p><b>handling</b>: <span title="Codes:{https://fevir.net/sevco STATO:0000090}">dichotomous variable</span></p><blockquote><p><b>category</b></p><p><b>name</b>: SGLT2 inhibitors</p><p><b>value</b>: <a href="Group-236769.html">Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors</a></p></blockquote><blockquote><p><b>category</b></p><p><b>name</b>: GLP-1 RA</p><p><b>value</b>: <a href="Group-236776.html">Glucagon-Like Peptide-1 (GLP-1) receptor agonists</a></p></blockquote></div>
  </text>
  <extension
             url="http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status">
    <valueCodeableConcept>
      <coding>
        <system
                value="http://terminology.hl7.org/CodeSystem/cited-artifact-status-type"/>
        <code value="active"/>
        <display value="Active"/>
      </coding>
    </valueCodeableConcept>
  </extension>
  <url value="https://fevir.net/resources/EvidenceVariable/236950"/>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="https://fevir.net/FOI"/>
    <value value="236950"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <identifier>
    <type>
      <text value="FEvIR Linking Identifier"/>
    </type>
    <system value="https://fevir.net/FLI"/>
    <value value="MAGIC-5288-j1Wqrn-group-assignment-85394-85798"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <identifier>
    <system value="urn:ietf:rfc:3986"/>
    <value value="urn:oid:2.16.840.1.113883.4.642.40.44.24.148"/>
  </identifier>
  <version value="1.0.0-ballot3"/>
  <name value="GroupAssignment_SGLT2_inhibitors_vs_GLP_1_RA"/>
  <title value="GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA"/>
  <citeAs
          value="GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236950. Revised 2026-08-06. Available at: https://fevir.net/resources/EvidenceVariable/236950. Computable resource at: https://fevir.net/resources/EvidenceVariable/236950#json."/>
  <status value="active"/>
  <date value="2026-11-05T14:34:28+00:00"/>
  <author>
    <name value="Computable Publishing®: MAGIC-to-FEvIR Converter"/>
  </author>
  <publisher value="HL7 International / Clinical Decision Support"/>
  <contact>
    <name value="HL7 International / Clinical Decision Support"/>
    <telecom>
      <system value="url"/>
      <value value="http://www.hl7.org/Special/committees/dss"/>
    </telecom>
  </contact>
  <description
               value="This EvidenceVariable Resource is referenced in an example for the EBMonFHIR Implementation Guide."/>
  <copyright
             value="Copyright the Authors else Computable Publishing LLC. Noncommercial use permitted with CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). Commercial use permitted as agreed in Terms of Use (https://fevir.net/termsofuse)."/>
  <relatesTo>
    <type>
      <coding>
        <system
                value="http://terminology.hl7.org/CodeSystem/artifact-relationship-type"/>
        <code value="part-of"/>
        <display value="Part Of"/>
      </coding>
    </type>
    <targetReference>
      <type value="Composition"/>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="MAGIC-5288-j1Wqrn-conversion-report"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <display
               value="MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"/>
    </targetReference>
  </relatesTo>
  <definition>
    <concept>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="defined-in-handling-and-category"/>
        <display value="Defined in handling and category elements"/>
      </coding>
    </concept>
  </definition>
  <handling>
    <coding>
      <system value="https://fevir.net/sevco"/>
      <code value="STATO:0000090"/>
      <display value="dichotomous variable"/>
    </coding>
  </handling>
  <category>
    <name value="SGLT2 inhibitors"/>
    <valueReference>🔗 
      <reference value="Group/236769"/>
      <type value="Group"/>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="MAGIC-5288-j1Wqrn-intervention-85394-I-85798"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <display value="Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors"/>
    </valueReference>
  </category>
  <category>
    <name value="GLP-1 RA"/>
    <valueReference>🔗 
      <reference value="Group/236776"/>
      <type value="Group"/>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="MAGIC-5288-j1Wqrn-comparator-85394-C-85798"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <display value="Glucagon-Like Peptide-1 (GLP-1) receptor agonists"/>
    </valueReference>
  </category>
</EvidenceVariable>